ANRS, Emerging Infectious Diseases: HIV Infections trials

The registry lists 66 HIV Infections studies with ANRS, Emerging Infectious Diseases as lead sponsor. 10 are open to participants now and 2 have results posted.

Phase 1 3Phase 2 18Phase 3 13No phase 37(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Detection of Specific Metabolic Signatures by Nuclear Magnetic Resonance or Metabolomic NMR in Correlation With Markers of Inflammation or Immune Activation and the Risk of Developing Neurocognitive Disorders - Longitudinal Retrospective Study Nested in the ANRS12225 PEDIACAM III CohortNot yet recruitingNCT07770568
• "Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort"Not yet recruitingNCT07412977
• Study of the Prevalence of Transmitted HIV-1 Resistance, Viral Diversity, and Cluster Identification in Patients at the Time of HIV-1 DiagnosisNot yet recruitingNCT07146529
• HIV-1 Non-group M in Cameroon : Study of Genotypic and Phylogenetic Diversity (OBSOCAM)Not yet recruitingNCT06913959
• Prevalence of Drug-resistant Hiv-1 Strains in Patients Experiencing Virologic Failure. (MULTIVIR2025)Not yet recruitingNCT06842706
• Assisted Notification of Partners of Men Having Sex With Men Discovering Their SeropositivityNot yet recruitingNCT06419491Not applicable
• Seroprevalence of Monkeypox Infection Among People Living With HIV and PrEP UsersNot yet recruitingNCT05922735
• Pilot Implementation of HIV Self-testing Delivery in Private Pharmacies Combined to a Respondent Driven Sampling Method to Improve HIV Testing for MSM and TGW in Phnom Penh - ANRS 0100sNot yet recruitingNCT05745168
• Assessment of HIV Remission Upon cART Interruption in Early Treated Individuals Carrying the MHC B35/53Bw4TTC2 GenotypeRecruitingNCT05482854Not applicable
• the ANRS CO21 " Extreme " Cohort (CODEX)RecruitingNCT01520844Not applicable
• Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy VolunteersCompletedNCT02038842Phase 1/2Results posted
• Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)CompletedNCT00928187Phase 3Results posted
• Negative Serology by Immunoenzymatic Test (EIA) in HIV-infected Children Treated Early With Antiretroviral in the ANRS-Pediacam Study: Pathophysiological MechanismsStatus unknownNCT06302933Not applicable
• Implementation and Effectiveness of Physical Activity to Prevent Disability in HIV-infected Adults Older Than 50 From Côte d'IvoireActive, not recruitingNCT06139497Not applicable
• Aging With HIV and Neurocognitive Decline, a Follow-up StudyCompletedNCT05385588Not applicable
• Large Scale Transition to a Dolutegravir-based First-line ART in the South: Virological Response and Impact on HIV Drug Resistance in a Real Life Context (DoReaL Study)CompletedNCT05312918
• Dual Therapy in HIV Patients in 4 Days a Week Versus 7 Days a WeekStatus unknownNCT04867083Phase 3
• ANRS 12392 Sanu GundoStatus unknownNCT04482010Not applicable
• HUSH Restriction in HIV Infected PatientsStatus unknownNCT04172480
• Evaluation of Triage Options After HPV Testing for Cervical Cancer Screening Among HIV-infected WomenStatus unknownNCT03789513Not applicable
• Role of the IL33/Amphiregulin Pathway as a Potential Therapeutic Target in HIV InfectionStatus unknownNCT03622177
• Evaluation of Third-line cART Regimen in Cambodia (3DICAM)Status unknownNCT03602690Phase 2
• Access to PrEP for MSM: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP)CompletedNCT03459157Not applicable
• A Chronological Study of the Formation of HIV Cellular Reservoirs Through the Expression of Surface Markers on CD4 + T Lymphocytes, Including CD32aCompletedNCT03298360
• Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected PatientsCompletedNCT03256422Phase 3
• Cohort of Patients Naive of Antiretroviral Treatment at EnrollmentCompletedNCT03137797
• Prevention of HIV in "Île-de-France"Status unknownNCT03113123Not applicable
• Co-adaptation Between Human Immunodeficiency Virus (HIV) and Cluster of Differentiation 8 (CD8) Cellular ImmunityCompletedNCT02886416
• CLEAC (Comparison of Late Versus Early Antiretroviral Therapy in HIV-infected Children)Status unknownNCT02674867Not applicable
• Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan AfricaCompletedNCT02626286Not applicable
• A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)CompletedNCT02527096Phase 2
• Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 PatientsCompletedNCT02384967Phase 2
• Human Papillomavirus Infection and Related Anal Lesions in HIV-positive Men Who Have Sex With MenCompletedNCT02287961Not applicable
• Disability and HIV: Vulnerability of People With Disabilities to HIV Infection in Sub-Saharan AfricaCompletedNCT02192658
• Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infectionCompletedNCT02125500Phase 2
• Third Line Antiretroviral Treatment Optimization in Sub-Saharan AfricaStatus unknownNCT02025868Phase 2
• Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infectionStatus unknownNCT01986543Phase 2
• X-linked Biological Response to HIV Sensing: the ANRS EP 53 StudyCompletedNCT01952587Not applicable
• IL-23/IL-12 Imbalance and T Lymphocyte Polarization in HIV InfectionCompletedNCT01942655Not applicable
• Early Identification and Treatment of Early HIV Infection in Côte d'IvoireCompletedNCT01917175
• Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in AfricaCompletedNCT01905059Phase 3
• Epicardial Adipose Tissue And Coronary Risk In HIV-Infected PatientsCompletedNCT01899196Not applicable
• Viral Biofilms: Hijacking T Cell Extracellular Matrix to Regulate HIV-1 Spread?CompletedNCT01895920Not applicable
• Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null RespondersCompletedNCT01725542Phase 2
• Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV IncidenceCompletedNCT01509508Not applicable
• On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With MenCompletedNCT01473472Phase 3
• Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin RegimenCompletedNCT01332955Phase 2
• Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot StudyCompletedNCT01207986Not applicable
• Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of AgeCompletedNCT01127204Phase 2/3
• Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve SubjectsCompletedNCT01066962Phase 3
• Residual Replication of HIV-1 in the Gut Associated Lymphoid Tissue (GALT) of Patients on Highly Active Antiretroviral Therapy (HAART): the ANRS EP 44 StudyCompletedNCT01038401Not applicable
• Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)CompletedNCT01033760Phase 3
• Raltegravir in Patients With End Stage Liver Disease and in Transplant RecipientsCompletedNCT01022476Phase 1/2
• Efficacy and Safety of Varenicline Among HIV-infected PatientsCompletedNCT00918307Phase 3
• Early and Intermittent Antiretroviral Therapy in Naive HIV Infected AdultsCompletedNCT00820118Phase 2
• Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine TrialsTerminatedNCT00789789
• Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)CompletedNCT00670839Phase 3
• Molecular Diversity of HIV-1 Group O Strains and Treatment Management in CameroonCompletedNCT00658346
• Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy VolunteersCompletedNCT00490074Phase 1/2
• Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected PatientsCompletedNCT00480792Phase 3
• Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 PrimevaCompletedNCT00424814Phase 2/3
• Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-infected Patients in Virological Failure.CompletedNCT00196625Phase 2
• Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAARTCompletedNCT00196612Phase 3
• Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected AdultsCompletedNCT00196599Phase 2
• Liver Transplantation in Patients With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) CoinfectionTerminatedNCT00158535Phase 2
• Antibody Responses to Pneumococcal Vaccines Among HIV-infected Adults.CompletedNCT00148824Phase 2